GGrantIndex
← Search

CORE--DNA MICROARRAY FACILITY

$285,268P30FY2009CANIH

Fox Chase Cancer Center, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

Microarray technology has broad applications in cancer research such as identification of cancer markers and gene expression profiling for diagnosis, treatment, and prognosis. Maintenance of a Core DNA Microarray Facility in a comprehensive cancer research center is critical for the success of a growing number of investigators with peer-reviewed funding. The Microarray Facility was established in 1999 using institutional and developmental funds from the CCSG. The Facility provides both printed cDNA and oligo arrays, for investigators to perform gene expression analysis, and full microarray services from RNA sample labeling to array scanning, for those investigators who do not have the capacity to perform microarray experiments in their own laboratories. The Facility also helps investigators to design and print custom microarrays to meet their specific research goals. The Facility is used by 20 investigators, all with peer-reviewed funding, from 9 research Programs in all three Divisions of Fox Chase Cancer Center (FCCC). The microarray usage has increased more than 200% from the year 2002 to 2003 and reached 1,300 microarrays per year. With an increasing number of research grants involving microarray analysis awarded recently, and the establishment of a Laser Capture Microdissection Facility at the Center, combined with RNA amplification procedure which enables small clinical cancer samples to be applied to microarray analysis, we anticipate a 100%-200% increase over the next five years. The microarray products of the Facility include human 40k cDNA and 30k oligo arrays, mouse 15k cDNA and 32k oligo arrays, and 6k yeast oligo arrays. A rat oligo library will be acquired to meet the needs of those investigators using rat models to study breast and ovarian oncogenesis. The Facility has also designed and produced customer design specific arrays, such as DNA repair process-related gene arrays. Standard microarray procedures and optimized labeling and hybridization kits, as well as a Microarray Training Program, have been made available to microarray users. A comprehensive microarray quality control procedure has been implemented to ensure the quality of microarray products and services. The Facility coordinates with the Bioinformatics Facility for microarray data analysis and management.

View original record on NIH RePORTER →